中华老年医学杂志
中華老年醫學雜誌
중화노년의학잡지
Chinese Journal of Geriatrics
2014年
1期
62-65
,共4页
前列腺肿瘤%前列腺特异抗原%碱性磷酸酶%二膦酸盐类
前列腺腫瘤%前列腺特異抗原%堿性燐痠酶%二膦痠鹽類
전렬선종류%전렬선특이항원%감성린산매%이련산염류
Prostatic Neoplasms%Prostate specific antigen%Alkaline phosphatase%Biphosphonates
目的 探讨前列腺特异性抗原(PSA)与骨形成标志物总碱性磷酸酶(tALP)、骨吸收标志物抗酒石酸酸性磷酸酶5b(TRACP5b)、Ⅰ型胶原吡啶交联终肽(ICTP)在前列腺癌骨转移患者治疗过程中反映骨代谢变化的意义. 方法 测定57例老年前列腺癌患者PSA、tALP、TRACP5b、ICTP血清浓度,采用Pearson相关分析法分析去势治疗持续时间与各指标浓度(ln转换后)的相关性.将前列腺癌骨转移患者分成无双膦酸盐组(A组)、稳定前列腺癌骨转移+双磷酸盐组(B组)与严重前列腺癌骨转移+双磷酸盐组(C组),比较3组间各标志物血清浓度的差异. 结果 去势治疗持续时间与PSA呈负相关,与tALP、ICTP及TRACP5b呈正相关,但仅ln(TRACP5b浓度)与ln(去势治疗持续时间)具有统计学意义(R=0.421,P＜0.01);C组与A组比较,PSA、TRACP5b、tALP浓度均升高,其中仅TRACP5b差异有统计学意义(P＜0.05);C组与B组比较,PSA、tALP、ICTP、TRACP5b浓度明显升高,差异均有统计学意义(P＜0.05). 结论 在前列腺癌骨转移患者的去势治疗与双磷酸盐治疗过程中,检测PSA与骨吸收形成标志物可起到监测骨代谢的变化作用,其中TRACP5b反应骨代谢变化更灵敏.
目的 探討前列腺特異性抗原(PSA)與骨形成標誌物總堿性燐痠酶(tALP)、骨吸收標誌物抗酒石痠痠性燐痠酶5b(TRACP5b)、Ⅰ型膠原吡啶交聯終肽(ICTP)在前列腺癌骨轉移患者治療過程中反映骨代謝變化的意義. 方法 測定57例老年前列腺癌患者PSA、tALP、TRACP5b、ICTP血清濃度,採用Pearson相關分析法分析去勢治療持續時間與各指標濃度(ln轉換後)的相關性.將前列腺癌骨轉移患者分成無雙膦痠鹽組(A組)、穩定前列腺癌骨轉移+雙燐痠鹽組(B組)與嚴重前列腺癌骨轉移+雙燐痠鹽組(C組),比較3組間各標誌物血清濃度的差異. 結果 去勢治療持續時間與PSA呈負相關,與tALP、ICTP及TRACP5b呈正相關,但僅ln(TRACP5b濃度)與ln(去勢治療持續時間)具有統計學意義(R=0.421,P＜0.01);C組與A組比較,PSA、TRACP5b、tALP濃度均升高,其中僅TRACP5b差異有統計學意義(P＜0.05);C組與B組比較,PSA、tALP、ICTP、TRACP5b濃度明顯升高,差異均有統計學意義(P＜0.05). 結論 在前列腺癌骨轉移患者的去勢治療與雙燐痠鹽治療過程中,檢測PSA與骨吸收形成標誌物可起到鑑測骨代謝的變化作用,其中TRACP5b反應骨代謝變化更靈敏.
목적 탐토전렬선특이성항원(PSA)여골형성표지물총감성린산매(tALP)、골흡수표지물항주석산산성린산매5b(TRACP5b)、Ⅰ형효원필정교련종태(ICTP)재전렬선암골전이환자치료과정중반영골대사변화적의의. 방법 측정57례노년전렬선암환자PSA、tALP、TRACP5b、ICTP혈청농도,채용Pearson상관분석법분석거세치료지속시간여각지표농도(ln전환후)적상관성.장전렬선암골전이환자분성무쌍련산염조(A조)、은정전렬선암골전이+쌍린산염조(B조)여엄중전렬선암골전이+쌍린산염조(C조),비교3조간각표지물혈청농도적차이. 결과 거세치료지속시간여PSA정부상관,여tALP、ICTP급TRACP5b정정상관,단부ln(TRACP5b농도)여ln(거세치료지속시간)구유통계학의의(R=0.421,P＜0.01);C조여A조비교,PSA、TRACP5b、tALP농도균승고,기중부TRACP5b차이유통계학의의(P＜0.05);C조여B조비교,PSA、tALP、ICTP、TRACP5b농도명현승고,차이균유통계학의의(P＜0.05). 결론 재전렬선암골전이환자적거세치료여쌍린산염치료과정중,검측PSA여골흡수형성표지물가기도감측골대사적변화작용,기중TRACP5b반응골대사변화경령민.
Objective To evaluate the significances of prostate specific antigen (PSA)and alkaline phosphatase(ALP) as a marker of bone formation and tartrate-resistant acid phosphatase 5b (TRACP5b)and pyridinoline cross-linked carboxy-terminal telopeptide of type Ⅰ collagen(ICTP)as markers of bone resorption in predicting therapeutic effect of bone metastasis of prostate cancer patients.Methods Serum levels of PSA,tALP,TRACP5b and ICTP in 57 elderly patients aged 61-90 years with prostate cancer were determined by electrochemiluminescence,colorimetric assay,enzyme linked immunosorbent assays(ELISA)respectively.The correlation between the duration of ADT and the concentrations of each marker index (ln-transformed) was analyzed by Pearson correlation analysis.All prostate cancer patients with bone metastasis were divided into group A (patients without bisphosphonates,n =13),group B (patients with stable bone metastasis and bisphosphonates,n=6) and group C (patients with severe bone metastasis and bisphosphonates,n=8).The concentration of each bone metabolic marker was compared between the three groups.Results Pearson correlation analysis showed that serum concentrations of PSA,ALP and ICTP had no significant correlations with the duration of ADT,but TRACP5b concentration (ln transformed) had a significant positive correlation with the duration of ADT (ln transformed) (R =0.421,P＜ 0.01).The concentrations of PSA,TRACP5b and tALP were increased in group C as compared with group A,but only TRACP5b concentration had a significant difference between group A and C (P＜ 0.05).The concentrations of PSA,tALP,ICTP and TRACP5b were significantly increased in group C as compared with group B (all P＜0.05).Conclusions PSA and bone resorption and formation markers can be excellent monitors of therapeutic effect-relating bone metabolism changes during castration and bisphosphonate treatment in prostate cancer patients with bone metastasis,and TRACP5b may be more sensitive.
